Equities

Ocuphire Pharma Inc

Ocuphire Pharma Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.46
  • Today's Change0.125 / 9.40%
  • Shares traded189.30k
  • 1 Year change-63.72%
  • Beta0.1861
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments514325
Total Receivables, Net2.334.85--
Total Inventory------
Prepaid expenses1.001.371.31
Other current assets, total0.100.08--
Total current assets544926
Property, plant & equipment, net00.010.01
Goodwill, net------
Intangibles, net------
Long term investments------
Note receivable - long term------
Other long term assets------
Total assets544926
LIABILITIES
Accounts payable2.151.071.58
Accrued expenses1.821.371.73
Notes payable/short-term debt000.54
Current portion long-term debt/capital leases------
Other current liabilities, total0.070.32--
Total current liabilities4.042.753.86
Total long term debt000
Total debt000.54
Deferred income tax------
Minority interest------
Other liabilities, total--00
Total liabilities4.042.753.86
SHAREHOLDERS EQUITY
Common stock0.000.000.00
Additional paid-in capital131118112
Retained earnings (accumulated deficit)(81)(71)(89)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity504622
Total liabilities & shareholders' equity544926
Total common shares outstanding242119
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.